Ortho Development earned FDA 510(k) clearance for its Trivecta hip system, the devicemaker said March 14.
Trivecta has a triple-taper femoral stem to fit a diverse range of patient anatomies, according to a news release. It also has sintered beads for initial and long-term stability, and Hydroxyapatite encourages biological fixation.
The implant will be available in the U.S. starting in the second quarter of 2024.